Loss of exclusivityNovember 2039latest FDA-listed patent expiry
CompanyChemoCentryx →View the full company profile on CliffBio
Drug detail
Brand name
TAVNEOS
Active ingredient
AVACOPAN
Strength
10MG
Dosage form
CAPSULE
Route
ORAL
Modality
Small molecule
FDA approval
October 2021
Marketing status
RX
Listed patents
Patent
Expires
Type
11603356
November 2039
substance, product
11951214
November 2039
product
8906938
January 2034
substance, product
8445515
February 2031
substance, product
Regulatory exclusivity
Code
Expires
ODE-377
October 2028
NCE
October 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.
TAVNEOS patent cliff — loss of exclusivity November 2039 | CliffBio